Please login to the form below

Not currently logged in
Email:
Password:

Lartruvo

This page shows the latest Lartruvo news and features for those working in and with pharma, biotech and healthcare.

EMA says Lilly’s Lartruvo should not be prescribed

EMA says Lilly’s Lartruvo should not be prescribed

Lilly said at the time it would stop promoting Lartruvo and would book a $70m-$90m charge this quarter as a result. ... Meanwhile, the trial failure also impacts Lartruvo in the US, as the FDA also approved the drug early on the promise of follow-up data.

Latest news

  • Lilly bags EU approval for cancer treatment Lartruvo Lilly bags EU approval for cancer treatment Lartruvo

    Licensed for use with doxorubicin for soft tissue sarcoma patients. The European Commission has granted Lilly's Lartruvo (orlaratumab) marketing authorisation for the first-line treatment of patients with advanced soft ... Until then, Lartruvo will be

  • Lilly snags first approval for sarcoma drug Lartruvo Lilly snags first approval for sarcoma drug Lartruvo

    Eli Lilly has picked up its first green light for its soft tissue sarcoma (STS) therapy Lartruvo, ending a four-decade drought for new front-line therapies. ... The US FDA granted accelerated approval to Lartruvo (olaratumab) used in combination with

  • Lilly closes on first approval for sarcoma drug Lartruvo Lilly closes on first approval for sarcoma drug Lartruvo

    Eli Lilly could be just weeks away from EU approval of its advanced soft tissue sarcoma (STS) treatment Lartruvo after a positive recommendation from the Committee for Medicinal Products for Human ... It is thought that by binding to the receptor

More from news
Approximately 4 fully matching, plus 0 partially matching documents found.

Latest Intelligence

  • Europe vs the US: New drug product approvals Europe vs the US: New drug product approvals

    Among the noteworthy approvals are Lartruvo (for the treatment of soft tissue sarcoma, approved in the EU and US), Rubraca (for the treatment of ovarian cancer, only approved in the US),

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Branding Science

We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...

Latest intelligence

International Childhood Cancer Day 2019
The number of new cases per year is shocking but the journey and the outlooks have vastly improved. We've pulled together an infographic to show just what we mean with...
Immuno-oncology in 2019: the rapid evolution continues
Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019?...
Mixing up Focus Groups
A nice spread of homogeneous participants in a focus groups are often a go to for reliable research outcomes but there's much to be said for mixing it up and...

Infographics